Sernova, a London, Ontario company, has announced positive results from an animal study testing the safety and efficacy of the company’s Cell Pouch System for treatment of diabetes. The details of the study, which involved porcine diabetes model, will be presented in August at the International Conference of the Transplant Society in Vancouver, British Columbia.
Some of the major findings of the study released by Sernova:
Long-term insulin independence was successfully achieved with significantly fewer islets than the current standard of care, requiring only about 10% of insulin-producing islets normally used for the Edmonton Protocol. Animals in the study achieved long-term glucose normalization throughout the course of the study. Standard laboratory tests demonstrated transplanted islets produced insulin and responded similarly to non-diabetic animals to provide control of glucose. No adverse events related to the Cell Pouch System(TM) occurred during the study.